Option chain shows key data for 's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for .

 (OTC:VGDFF) Stock, Option Chain

Biotech

News

General

NRXP

NRx Pharmaceuticals Publishes Study In American Journal Of Clinical Psychopharmacology Highlighting Enhanced Depression Rating Reliability In Phase 2b/3 NRX-101 Trial, Supporting Future Registration Trials For Antidepressant Drugs

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Buy and raises the price target from $42 to $45.

Price Target

Analyst Ratings

BBIO

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $45

CTXR

Citius Pharmaceuticals Announces Type C Meeting With FDA, Says FDA Provided Guidance Underscoring Pathway To Support A Future NDA Submission For Mino-Lok

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">143.6300</td>
<td align="right">0.980</td>
<td align="right">0.68</td>
<td>1.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.0100</td>
<td align="right">0.280</td>
<td align="right">0.55</td>
<td>94.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">144.8211</td>
<td align="right">0.661</td>
<td align="right">0.45</td>
<td>3.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">234.6500</td>
<td align="right">1.050</td>
<td align="right">0.44</td>
<td>29.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.7750</td>
<td align="right">0.325</td>
<td align="right">0.39</td>
<td>17.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">44.2600</td>
<td align="right">0.170</td>
<td align="right">0.38</td>
<td>1.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">97.6367</td>
<td align="right">0.367</td>
<td align="right">0.37</td>
<td>10.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.9900</td>
<td align="right">0.150</td>
<td align="right">0.18</td>
<td>6.6K</td>
</tr>
</tbody>
</table>
No loser in today's Pre-market session. 
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Leading And Lagging Sectors For November 25, 2024

WIIM

BHVN

Biohaven shares are trading lower after the company announced its treatment arm of the RESILIENT SMA study did not statistically separate on the primary outcome at Week 48 compared to the placebo+standard of care group.

DA Davidson analyst Linda Bolton Weiser maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Buy and maintains $170 price target.

DA Davidson Maintains Buy on e.l.f. Beauty, Maintains $170 Price Target

IMNN

IMUNON Secures FDA Support For Phase 3 Trial Of IMNN-001 In Advanced Ovarian Cancer, Plans To Submit Final Protocol In December And Launch 500-Patient Study In Q1 2025

VSTE

Vast shares are trading higher after the company signed an updated funding agreement to access up to $30 million of its $65 million grant from the Australian Renewable Energy Agency.

-- Webcast to be held on Monday, December 2, 2024 at 8:30 AM Eastern Time --
Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place on Monday, December 2 at 8:30 AM Eastern Time and will review recent manufacturing process enhancements, biomarker characterization analyses, and the Company's future plans for the program.
Webcast Information
The live webcast may be accessed by visiting Rallybio's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.rallybio.com&amp;esheet=54157145&amp;newsitemid=20241122010570&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.rallybio.com&amp;index=1&amp;md5=ebebb87ed962863ea700cd114690d68e">http://investors.rallybio.com</a>. A replay and accompanying slides of the webcast will be available on the Rallybio website for 30 days following the event.

RLYB

Rallybio To Provide Update On RLYB116 Program, An Innovative Subcutaneously Injected C5 Inhibitor; Webcast To Be Held On Monday, December 2, 2024 At 8:30 am ET

SAVA

Cassava Sciences  shares are trading lower after the company announced Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study.

ALUR

Allurion Launches AllurionMeds In The U.S., Combining AI-Driven GLP-1 Weight Loss Program With Coach Iris For Long-Term Maintenance, Expanding Reach To All 50 States And Advancing Mission To Combat Obesity

BridgeBio Pharma shares are trading higher after the company announced that the FDA approved Attruby to treat adults with ATTR-CM. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $43 to $49.

Small Cap Consumer Research analyst Eric Beder reiterates Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Buy and maintains $29 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Guess, Maintains $29 Price Target

Canaccord Genuity analyst Joseph Vafi maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $300 to $510.

MSTR

Canaccord Genuity Maintains Buy on MicroStrategy, Raises Price Target to $510

Financing

Vast Signs Updated Funding Agreement To Access Up To $30M Of Its $65M Grant From The Australian Renewable Energy Agency

Brightcove Stockholders to Receive $4.45 Per Share in Cash
Bending Spoons enters the enterprise SaaS market and will draw on its technology expertise to further strengthen Brightcove and bring its cutting-edge platform to new heights
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect-us.mimecast.com%2Fs%2FTT0ACXD7rNIDpARJTkWLIt%3Fdomain%3Dbrightcove.com&amp;esheet=54157477&amp;newsitemid=20241124779994&amp;lan=en-US&amp;anchor=Brightcove+Inc.&amp;index=1&amp;md5=4089cc9217606a25bce452fc6f364d4e">Brightcove Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOV#NASDAQ">BCOV</a>), the world's most trusted streaming technology company, today announced that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $233 million. Under the terms of the agreement, Brightcove shareholders will receive $4.45 per share in cash for each share of Brightcove common stock that they own. The per share purchase price represents a 90% premium over Brightcove's 60-day volume weighted average share price as of the close on November 22, 2024.

BCOV

Brightcove Enters Into Definitive Agreement To Be Acquired By Bending Spoons For $233M; Brightcove Stockholders To Receive $4.45 Per Share In Cash

Tsetsaut Skii km Lax Ha Nation Files For Judicial Review Of B.C.'s Substantial Start Determination For Seabridge Gold's KSM Mine; Despite Seabridge's Plan To Locate The Mine's Immense Toxic Waste Facilities On The Nation's Exclusive Traditional Territory, The Province Has Not Engaged In The Meaningful Consultation Required By The Canadian Constitution

TOYO

Toyo Co. To Acquire Texas-Based Solar Module Manufacturing Facility With Initial 2.5 GW Capacity, Plans Expansion To 6.5 GW By 2029 To Meet U.S. Demand For American-Made Solar Panels; Financial Terms Not Disclosed

B of A Securities analyst Alec Stranahan downgrades Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) from Buy to Neutral and lowers the price target from $24 to $6.

Downgrades

CATX

B of A Securities Downgrades Perspective Therapeutics to Neutral, Lowers Price Target to $6

Telsey Advisory Group analyst Dana Telsey maintains Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) with a Market Perform and maintains $8 price target.

CURV

Telsey Advisory Group Maintains Market Perform on Torrid Holdings, Maintains $8 Price Target

Vanguard US Trsy 0-1 YR Bond UCITS ETF - USD Acc

Comments

(VGDFF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga